Proton Pump Inhibitors Increases Longitudinal Risk of Mortality, Decompensation, and Infection in Cirrhosis: A Meta-Analysis.
暂无分享,去创建一个
K. Siah | M. Noureddin | K. Wijarnpreecha | M. Muthiah | A. Kaewdech | D. Tan | W. Lim | B. Nah | Douglas Chee | Z. Wong | Margaret Teng | Benjamin Koh | Kai-Qi Ou | Elden Yen Hng Ong | Jia Hong Koh | C. Ong | Cheng Han Ng | Daniel Q. Huang | Yujun Wong | Anand V Kulkarni | E. Ong | Anand V. Kulkarni
[1] J. Higgins,et al. Tenets for the Proper Conduct and Use of Meta-Analyses: A Practical Guide for Neurosurgeons. , 2022, World neurosurgery.
[2] H. Yoshiji,et al. Baveno VII - Renewing consensus in portal hypertension. , 2021, Journal of hepatology.
[3] Hong Zhao,et al. Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study , 2021, Frontiers in Medicine.
[4] N. Befera,et al. Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort. , 2021, Clinical imaging.
[5] R. Moreau,et al. The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis. , 2020, Journal of hepatology.
[6] E. Tapper,et al. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] Krishnakant V. Saboo,et al. Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis. , 2020, The American journal of gastroenterology.
[8] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[9] Y. Chan,et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis , 2019, World journal of gastroenterology.
[10] A. Lok,et al. Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis , 2019, Hepatology communications.
[11] E. Kelly,et al. Clinical Factors Associated with Mortality in Cirrhotic Patients Presenting with Upper Gastrointestinal Bleeding , 2019, Journal of the Canadian Association of Gastroenterology.
[12] P. Andersen,et al. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[13] Tony P. Smith,et al. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. , 2019, Journal of vascular and interventional radiology : JVIR.
[14] A. Farcomeni,et al. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis , 2018, Hepatology.
[15] Lifeng Lin,et al. Quantifying publication bias in meta‐analysis , 2018, Biometrics.
[16] M. Manns,et al. Dose‐dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[17] K. Jones,et al. Fixed and random effects models: making an informed choice , 2018, Quality & Quantity.
[18] Chen-Chi Tsai,et al. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. , 2018, Clinics and research in hepatology and gastroenterology.
[19] C. Tovo,et al. Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis , 2017, World journal of hepatology.
[20] R. Chung,et al. Use of proton pump inhibitors in chronic liver diseases , 2017, Clinical liver disease.
[21] Michelle L Degelman,et al. Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation. , 2017, Multiple sclerosis and related disorders.
[22] P. Hayes,et al. The impact of proton pump inhibitor therapy on patients with liver disease , 2016, Alimentary pharmacology & therapeutics.
[23] Ji-An Liang,et al. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. , 2016, European journal of internal medicine.
[24] Angela C. Poole,et al. Proton pump inhibitors alter the composition of the gut microbiota , 2015, Gut.
[25] Jingyuan Fu,et al. Proton pump inhibitors affect the gut microbiome , 2015, Gut.
[26] Nora C. Toussaint,et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. , 2015, Gastroenterology.
[27] Zachary A. Capshaw,et al. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology , 2015, Emerging Themes in Epidemiology.
[28] K. Brandl,et al. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? , 2015, Expert review of gastroenterology & hepatology.
[29] F. Barreyro,et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. , 2015, Journal of hepatology.
[30] J. Turner,et al. Dysbiosis‐induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice , 2015, Hepatology.
[31] B. Kronenberger,et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis , 2015, Alimentary pharmacology & therapeutics.
[32] J. González-Navajas,et al. Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis , 2015, Journal of gastroenterology and hepatology.
[33] S. Bota,et al. Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites , 2014, PloS one.
[34] Y. Paik,et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study , 2014, Alimentary pharmacology & therapeutics.
[35] Ji Won Kim,et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis , 2014, Journal of gastroenterology and hepatology.
[36] P. Deltenre,et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[37] Walter Wai-Yip Chan,et al. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[38] K. Reddy,et al. Second infections independently increase mortality in hospitalized patients With cirrhosis: the north american consortium for the study of end‐stage liver disease (NACSELD) experience , 2012, Hepatology.
[39] K. Lapane,et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis , 2012, Alimentary pharmacology & therapeutics.
[40] P. Siersema,et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability , 2012, European journal of clinical investigation.
[41] K. Reddy,et al. Immune dysfunction and infections in patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[42] R. Hoffmann,et al. Association of Proton Pump Inhibitor Therapy With Spontaneous Bacterial Peritonitis in Cirrhotic Patients With Ascites , 2009, The American Journal of Gastroenterology.
[43] John Fletcher,et al. What is heterogeneity and is it important? , 2007, BMJ : British Medical Journal.
[44] N. Shaheen,et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial , 2005, Hepatology.
[45] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[46] R. Balbinot,et al. ACUTE-ON-CHRONIC LIVER FAILURE IS INDEPENDENTLY ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS. , 2021, Arquivos de gastroenterologia.